Core Viewpoint - He Yuan Bio is the first company to be reviewed under the newly established fifth set of standards for the Sci-Tech Innovation Board, following the announcement of the growth tier for unprofitable companies [2][4]. Company Overview - He Yuan Bio, established in 2006, focuses on the research and development of innovative drugs, with its core product HY1001 (recombinant human albumin injection) having completed Phase III clinical trials and included in the priority review process by the National Medical Products Administration [4][5]. - The company has not yet generated revenue from its core innovative drug products, with current income primarily from pharmaceutical excipients and research reagents [5]. Financial and Operational Insights - He Yuan Bio has invested a total of 386 million yuan in R&D from 2022 to 2024, with a workforce of 178 employees, of which 122 are dedicated to R&D, accounting for nearly 70% [5]. - The innovative drug industry typically requires significant R&D investment and long development cycles, which contributes to He Yuan Bio's current lack of profitability [5]. Product Development and Market Position - The core product HY1001 aims to supplement or enhance the levels of human serum albumin in the blood, potentially replacing plasma-derived human serum albumin, which is currently widely used in clinical settings but largely imported [6]. - He Yuan Bio has achieved breakthroughs in increasing the expression levels and purity of recombinant human albumin, reducing production costs and enhancing clinical safety, with related technology awarded the National Technology Invention Award (Second Class) [6]. Industry Context - As of 2024, the 20 companies listed under the fifth set of standards on the Sci-Tech Innovation Board collectively generated over 14 billion yuan in revenue, a growth of over 40% compared to 2023 [8]. - The first quarter of 2025 saw these companies achieve a combined revenue of 3.78 billion yuan, reflecting a year-on-year growth of 29.27% [8]. - The fifth set of standards has supported the listing of high-quality tech companies that have not yet formed significant revenue scales, demonstrating the adaptability and inclusiveness of the Sci-Tech Innovation Board [9].

Summary of Key Points from Conference Call Records Industry Overview - The conference call primarily discusses the **pharmaceutical industry** and its recovery driven by **policy support**, **funding inflow**, **AI technology**, and **innovation in drug development**. [1][2][4] Core Insights and Arguments 1. **Pharmaceutical Sector Recovery**: The pharmaceutical sector has shown signs of recovery, with the biopharmaceutical index outperforming the CSI 300 index, and the pharmaceutical sector increasing by **28%**. This recovery is attributed to supportive policies, funding inflow, AI technology advancements, and the international expansion of innovative drugs. [2][4] 2. **Innovative Drug Development**: In the first four months, the total amount of business development (BD) events in innovative drugs reached **$55 billion**, with upfront payments exceeding **$5 billion**, indicating strong market recognition of China's innovative drug development capabilities. [1][3][5] 3. **Investment Focus for H2 2025**: The main investment themes for the second half of 2025 include innovative drugs, AI medical technology, the silver economy, and emerging medical technologies empowered by AI, such as protein prediction. [1][4] 4. **Demographic Changes Impacting Consumption**: The decline in newborn population is weakening traditional consumption demand, while the pet economy is rapidly growing. The increasing proportion of elderly people is driving the development potential of the silver economy and health industry. [1][6] 5. **AI Technology in Pharmaceuticals**: AI technology is enhancing the pharmaceutical industry by improving research efficiency and reducing costs, particularly in protein prediction and innovative therapy development. [2][7] Additional Important Insights 1. **Clinical Data Driving Market Confidence**: The performance of innovative drug companies is expected to remain strong, with significant BD activities and impressive financial reports anticipated for the second half of 2025. [9][10] 2. **Challenges in the Pharmaceutical Supply Chain**: Hospitals face challenges in drug supply, emphasizing the need for innovative drugs to demonstrate significant clinical value and effectiveness. [18] 3. **Insurance and Policy Developments**: The introduction of commercial insurance policies is expected to stimulate the innovative drug sector positively, with ongoing adjustments to the medical insurance directory providing negotiation opportunities for companies. [11][21] 4. **Emerging Consumer Trends**: The rise of new consumer demographics, particularly among younger generations, is reshaping consumption patterns, with a notable increase in spending on pet-related products and services. [30][31] 5. **Pet Industry Growth**: The pet industry is experiencing rapid growth, with the market size reaching **300.2 billion yuan** by 2024, driven by an increase in pet ownership and spending on pet care. [53][54] This summary encapsulates the key points discussed in the conference call, highlighting the pharmaceutical industry's recovery, the impact of AI technology, demographic changes, and emerging consumer trends in the pet industry.

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index has shown a positive trend, with notable increases in constituent stocks such as Zhenhua Cell and Rongchang Biopharmaceutical [1][3] - The Jiashi Sci-Tech Medicine ETF has experienced significant trading activity and growth, leading in both scale and share increase among comparable funds [3][6] Market Performance - As of June 24, 2025, the Sci-Tech Innovation Board Biopharmaceutical Index rose by 0.82%, with Zhenhua Cell up by 9.46% and Rongchang Biopharmaceutical up by 4.23% [1] - The Jiashi Sci-Tech Medicine ETF recorded a turnover of 8.8% and a transaction volume of 18.05 million yuan, with an average daily transaction of 41.47 million yuan over the past month [3] Fund Growth - The Jiashi Sci-Tech Medicine ETF has seen a scale increase of 128 million yuan over the past year, leading among comparable funds [3] - The fund's net asset value has increased by 21.01% over the past year, with a historical one-year profit probability of 72.17% [3][6] Top Holdings - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index account for 51.6% of the index, with leading companies including United Imaging Healthcare and BeiGene [3][5] Industry Trends - Recent significant licensing deals in the Chinese innovative pharmaceutical sector include a $6 billion deal by 3SBio and a $5.33 billion strategic collaboration between CSPC and AstraZeneca [5][6] - Chinese innovative pharmaceutical companies are demonstrating competitive advantages in R&D efficiency and cost control, particularly in advanced technology fields such as ADC and cell therapy [6]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Views - The investment value of the pharmaceutical and biotechnology industry is highlighted due to accelerated review and approval processes for innovative drugs, along with optimized listing standards [4][6] - Recent policies from the NMPA and CDE are expected to significantly shorten the development cycle for innovative drugs and alleviate cash flow pressures for biotech companies [7][24] Industry Review - The pharmaceutical and biotechnology industry index experienced a decline of 3.01%, ranking 17th among 31 primary industries, underperforming the CSI 300 index which fell by 0.71% [5][15] - The PE ratio (TTM, excluding negative values) for the industry as of June 20, 2025, is 27.28x, down from 28.24x in the previous period, indicating a downward trend in valuation [19][21] Important Industry News - The NMPA has released a draft for optimizing the review and approval of clinical trials for innovative drugs, aiming to complete reviews within 30 working days for eligible applications [24][25] - The CDE's annual report on new drug registration clinical trials indicates a steady increase in clinical trials, particularly in oncology and autoimmune disease areas, reflecting a positive trend in drug development [34][35] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with clear clinical value and strong commercialization capabilities, as well as CXO companies with international potential, to capitalize on valuation recovery opportunities driven by policy catalysts [7][6]

Core Insights - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China (ICBC) Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of ICBC Healthcare Stock Fund is 2.5760 yuan, reflecting a growth of 1.18% - The fund's return over the past month is -0.46%, ranking 514 out of 1026 in its category - Over the last six months, the fund has achieved a return of 11.85%, ranking 173 out of 993 - Year-to-date, the fund has returned 13.03%, ranking 137 out of 997 [1]. Fund Holdings - The top ten holdings of the ICBC Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuyue Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, with Zhao having extensive experience in healthcare research and fund management [2].

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 1.27% on June 19, with a latest net value of 2.56 yuan, marking a cumulative drop of 7.84% over five consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.724 billion yuan and a cumulative return of 156.40% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of March 31, 2025, the top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with major positions including: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuwell Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [3]

Group 1: ETF Performance - The liquidity of the Science and Technology Innovation Pharmaceutical ETF (嘉实) showed an intra-day turnover of 14.75%, with a transaction volume of 29.7999 million yuan, indicating active market trading [2] - Over the past year, the ETF's scale increased by 125 million yuan, ranking first among comparable funds [2] - The ETF's net asset value rose by 20.29% over the past year, with the highest monthly return since inception being 23.29% and an average monthly return of 8.18% [2] Group 2: Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index accounted for 51.6% of the index, with leading companies including 联影医疗 (8.97%), 百济神州 (7.05%), and 惠泰医疗 (5.85%) [2][4] Group 3: Regulatory Updates - The National Medical Products Administration released a draft announcement to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [4] Group 4: Industry Events - The American Diabetes Association Annual Meeting (ADA) will take place from June 20 to 23, showcasing key clinical advancements in GLP-1RA research and related medications [5]

Investment Rating - The report assigns an "Accumulate" rating to the company, marking its first coverage [3][8]. Core Insights - The company focuses on the NSCLC small molecule innovative drug sector, possessing both second and third generation ALK-TKIs, with significant advancements in its clinical pipeline [3][17]. - The commercial value of the second generation ALK-TKI is about to be realized, while the third generation ALK-TKI is progressing well in clinical trials [4][60]. - The company has multiple early-stage research projects that have achieved significant milestones, ensuring sustainable development [3][18]. Summary by Sections Section 1: Focus on NSCLC Small Molecule Innovative Drugs - The company specializes in the independent research and development of small molecule innovative drugs, with a pipeline that includes various tumor indications and urgent clinical needs [3][17]. - It is the first domestic company to have both second and third generation ALK-TKIs [3][17]. - As of the 2024 report, the company has 22 proprietary research pipelines, all classified as new drugs [17][18]. Section 2: Commercial Value of ALK-TKIs - The second generation ALK-TKI SY-707 is nearing commercialization, with its NDA accepted by NMPA [4][55]. - The third generation ALK-TKI SY-3505 is the fastest progressing domestic option, with ongoing key clinical trials [4][58]. - The ALK-TKI market in China is dominated by second generation products, which are expected to account for 67.33% of the market by 2024 [60]. Section 3: SY-5007 and RET-TKI Development - SY-5007 is a high-selectivity RET-TKI that is currently in phase III clinical trials, showing promising efficacy and safety [6][22]. - It is the only domestic selective RET-TKI that has entered phase III trials globally, providing a significant competitive edge [6][22]. Section 4: Financial Projections - The company is projected to generate revenues of 0.59 billion, 1.43 billion, and 2.87 billion RMB from 2025 to 2027, with net losses expected to decrease slightly over the same period [7][10]. - The total equity value of the company is estimated at 6.614 billion RMB based on DCF modeling [7][8].

Core Insights - The latest net value of ICBC Medical Care Stock (000831) is 2.5970 yuan, reflecting a decrease of 0.65% [1] - The fund has shown a monthly return of 3.76%, ranking 221 out of 922 in its category, a six-month return of 11.08% with a ranking of 162 out of 898, and a year-to-date return of 13.95%, ranking 134 out of 901 [1] Fund Holdings - The top ten holdings of ICBC Medical Care Stock account for a total of 39.79%, with the largest positions being: - Heng Rui Medicine (8.90%) - WuXi AppTec (5.12%) - Aier Eye Hospital (4.94%) - BeiGene (3.77%) - Zai Lab (3.52%) - New Horizon Health (3.27%) - Mindray Medical (2.80%) - Yuyue Medical (2.76%) - United Imaging Healthcare (2.47%) - Innovent Biologics (2.24%) [1] Fund Management - ICBC Medical Care Stock was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, with Zhao having extensive experience in healthcare research and fund management since joining ICBC Credit Suisse in 2010 [2]

加力推出进一步深化改革的"1+6"政策措施。 在"科创板八条"发布一周年之际，科创板再迎重磅改革举措。 6月18日，中国证监会主席吴清在2025陆家嘴论坛上表示，在新起点上，将继续充分发挥科创板示范效 应，加力推出进一步深化改革的"1+6"政策措施。 据吴清介绍，"1"即在科创板设置科创成长层，并且重启未盈利企业适用科创板第五套标准上市；"6"即 在科创板创新推出6项改革措施，包括对于适用科创板第五套标准的企业，试点引入资深专业机构投资 者制度；面向优质科技企业试点IPO预先审阅机制；扩大第五套标准适用范围。同时，将在创业板正式 启用第三套标准，支持优质未盈利创新企业上市。 在一年前的6月19日，证监会发布《关于深化科创板改革服务科技创新和新质生产力发展的八条措施》 （简称"科创板八条"）。这一年来，科创板发生了怎样的变化？ 这一年，科创板改革从纸面走向实践，8方面30余项改革举措渐次落地，涉及支持硬科技企业上市、优 化发行承销制度、再融资、并购重组、指数产品及市场生态等方面。 具体而言，4家未盈利企业的IPO申请获得受理，拟募资金额合计超160亿元；新上市企业15家，合计募 集资金124亿元；9家符合"轻资 ...